Finanztrends
Deine Einschätzung
Syndax Pharmaceuticals Inc Aktie
Einen Verlust von -6,55 % verzeichnet heute die Syndax Pharmaceuticals Inc Aktie.
Bei der Bewertung der Syndax Pharmaceuticals Inc Aktie dominiert in der Community die positive Sicht, angeführt vom Kriterium Lohnenswerte Investition für die nächsten Jahre.
Was spricht für und gegen Syndax Pharmaceuticals Inc in den nächsten Jahren?
Pro
?
M************
?
L*********** I********** f** d** n******* J****
?
W******* i* V********
Kontra
?
M****
?
A****************
?
U****************
Sag auch du wie 2 andere deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Syndax Pharmaceuticals Inc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | -6,55 % | 1,85 % | 18,28 % | 94,69 % | 22,91 % | 14,58 % | 15,18 % |
| Rockwell Medical Inc. | 1,73 % | 8,86 % | 6,29 % | -9,84 % | 19,88 % | -51,20 % | -92,25 % |
| Pacira Pharmaceuticals | -2,55 % | -1,01 % | 0,00 % | -4,85 % | -9,26 % | -46,74 % | -67,06 % |
| Twist Bioscience Corp | -1,63 % | 12,62 % | 3,84 % | 31,60 % | 56,41 % | 255,30 % | -58,08 % |
Kommentare
News
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
DAFNA Capital Management reported selling 222,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.89 million based on
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $8.18
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
On February 17, 2026, Sphera Funds Management Ltd. disclosed a purchase of 374,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $6.54 million trade based on quarterly average